[go: up one dir, main page]

NO20076145L - Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav - Google Patents

Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav

Info

Publication number
NO20076145L
NO20076145L NO20076145A NO20076145A NO20076145L NO 20076145 L NO20076145 L NO 20076145L NO 20076145 A NO20076145 A NO 20076145A NO 20076145 A NO20076145 A NO 20076145A NO 20076145 L NO20076145 L NO 20076145L
Authority
NO
Norway
Prior art keywords
ureadeviates
processes
preparation
compounds
formula
Prior art date
Application number
NO20076145A
Other languages
English (en)
Norwegian (no)
Inventor
Helene Jary
Taoues Temal
Pierre Deprez
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Publication of NO20076145L publication Critical patent/NO20076145L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Treating Waste Gases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20076145A 2005-04-29 2007-11-28 Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav NO20076145L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504360A FR2885129B1 (fr) 2005-04-29 2005-04-29 Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
PCT/EP2006/004166 WO2006117211A2 (fr) 2005-04-29 2006-04-24 Derives d'uree, procedes pour leur fabrication et utilisations de ces derives

Publications (1)

Publication Number Publication Date
NO20076145L true NO20076145L (no) 2008-01-28

Family

ID=35311522

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076145A NO20076145L (no) 2005-04-29 2007-11-28 Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav

Country Status (25)

Country Link
US (2) US8247412B2 (fr)
EP (2) EP1874765B1 (fr)
JP (1) JP4995189B2 (fr)
KR (1) KR20080003380A (fr)
CN (1) CN101238120A (fr)
AR (1) AR056991A1 (fr)
AT (1) ATE548368T1 (fr)
AU (1) AU2006243328B2 (fr)
BR (1) BRPI0611025A2 (fr)
CA (1) CA2605008A1 (fr)
CR (1) CR9469A (fr)
CY (1) CY1112960T1 (fr)
DK (1) DK1874765T3 (fr)
EA (1) EA200702375A1 (fr)
ES (1) ES2384052T3 (fr)
FR (1) FR2885129B1 (fr)
HR (1) HRP20120424T1 (fr)
IL (1) IL186854A0 (fr)
NO (1) NO20076145L (fr)
PL (1) PL1874765T3 (fr)
PT (1) PT1874765E (fr)
TW (1) TW200714598A (fr)
UY (1) UY29510A1 (fr)
WO (1) WO2006117211A2 (fr)
ZA (1) ZA200708871B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP1965805B1 (fr) * 2005-11-25 2009-12-02 Galapagos SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
WO2007124465A2 (fr) * 2006-04-20 2007-11-01 Amgen Inc. Formules d'émulsions stables
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
CA2681582C (fr) 2007-03-30 2015-07-14 Amgen Inc. Procedes de traitement de troubles intestinaux
JP5321452B2 (ja) * 2007-05-08 2013-10-23 味の素株式会社 下痢の予防又は治療剤
CA2692598A1 (fr) * 2007-07-10 2009-01-15 Amgen Inc. Derives de l'uree et de diamines associees, leurs procedes de fabrication, et leurs utilisations
WO2010104882A1 (fr) 2009-03-10 2010-09-16 Amgen Inc. Procédés de modulation de la motilité des spermatozoïdes
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2015002926A1 (fr) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Dérivés pyrido-carboxamides tricycliques servant d'inhibiteurs de rock
EP3265448B1 (fr) * 2015-03-03 2021-12-29 Biohaven Pharmaceutical Holding Company Ltd. Promédicaments de riluzole et leur utilisation
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
WO2019222393A1 (fr) * 2018-05-15 2019-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions neuroprotectrices et leurs méthodes d'utilisation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31574A0 (en) 1968-02-13 1969-04-30 Ciba Ltd Use of certain ureas for combating weeds
US3897242A (en) 1968-02-13 1975-07-29 Ciba Geigy Ag Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4521583A (en) 1984-02-09 1985-06-04 American Cyanamid Company Curable epoxy resin compositions
US4594373A (en) 1984-02-09 1986-06-10 American Cyanamid Company Curable epoxy resin compositions
FR2601363B1 (fr) * 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
US5227397A (en) 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
CA2062810A1 (fr) 1989-07-03 1991-01-04 Bruce D. Cherksey Utilisation de polyamines comme agents de regulation de la circulation ionique trans-membranaire
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
ATE196466T1 (de) 1990-11-19 2000-10-15 Monsanto Co Inhibitoren retroviraler proteasen
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995011221A1 (fr) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Arylalkylamines agissant sur les recepteurs du calcium
CA2131182C (fr) 1992-05-20 2005-04-26 John S. Ng Methode de production d'intermediaires utilises dans la synthese des inhibiteurs de la protease retrovirale
EP1302468B1 (fr) 1992-12-29 2008-12-17 Abbott Laboratories Procédés et intermédiaires pour la préparation d'inhibiteurs de protéase rétrovirale
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
HU228150B1 (en) 1994-10-21 2012-12-28 Nps Pharma Inc Calcium receptor-active compounds, medicaments comprising them, and the use of said medicaments
CA2180021A1 (fr) 1994-11-04 1996-05-17 Yoichi Kawashima Nouveau derive de 1,3-dialkyluree ayant un groupe hydroxyle
DE69528197T2 (de) 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
JP3306571B2 (ja) 1995-06-28 2002-07-24 参天製薬株式会社 エンドセリン変換酵素阻害剤
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
CA2197364A1 (fr) 1996-02-15 1997-08-16 Toshikazu Suzuki Compose phenolique et methode de preparation
WO1997037967A1 (fr) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Composes calcilytiques
JP2003524574A (ja) 1997-08-05 2003-08-19 ノボ ノルディスク アクティーゼルスカブ ２，５−及び３，５−二置換アニリン誘導体、その調製及び使用
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
WO1999037604A2 (fr) 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkylurees utilisees en tant que substances imitant la calcitonine
EP2308833A3 (fr) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Inhibiteurs de kinase de tyrosine de protéine cyclique
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6598746B2 (en) * 2001-09-13 2003-07-29 Washburn Graphics, Inc. Display carton having an internally reinforced hanger panel
WO2004030669A1 (fr) 2002-09-30 2004-04-15 Schering Corporation Utilisation d'amides tricycliques en vue de traiter des troubles lies a l'homeostasie calcique
JP2005336173A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 骨粗鬆症治療剤
US8362274B2 (en) 2004-05-28 2013-01-29 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US7585886B2 (en) 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
EP1965805B1 (fr) 2005-11-25 2009-12-02 Galapagos SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
CA2692598A1 (fr) 2007-07-10 2009-01-15 Amgen Inc. Derives de l'uree et de diamines associees, leurs procedes de fabrication, et leurs utilisations

Also Published As

Publication number Publication date
AR056991A1 (es) 2007-11-07
US8247412B2 (en) 2012-08-21
CY1112960T1 (el) 2016-04-13
CN101238120A (zh) 2008-08-06
TW200714598A (en) 2007-04-16
CR9469A (es) 2008-03-06
ATE548368T1 (de) 2012-03-15
EP1874765B1 (fr) 2012-03-07
ZA200708871B (en) 2009-03-25
ES2384052T3 (es) 2012-06-28
EP1874765A2 (fr) 2008-01-09
FR2885129A1 (fr) 2006-11-03
DK1874765T3 (da) 2012-06-18
FR2885129B1 (fr) 2007-06-15
WO2006117211A2 (fr) 2006-11-09
EA200702375A1 (ru) 2008-06-30
US20120283255A1 (en) 2012-11-08
US20100240889A1 (en) 2010-09-23
BRPI0611025A2 (pt) 2016-11-16
WO2006117211A3 (fr) 2007-01-11
PL1874765T3 (pl) 2012-08-31
IL186854A0 (en) 2008-02-09
HRP20120424T1 (hr) 2012-06-30
EP2354137A1 (fr) 2011-08-10
UY29510A1 (es) 2006-12-29
CA2605008A1 (fr) 2006-11-09
PT1874765E (pt) 2012-05-25
KR20080003380A (ko) 2008-01-07
AU2006243328B2 (en) 2011-09-08
JP2008539186A (ja) 2008-11-13
JP4995189B2 (ja) 2012-08-08
AU2006243328A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NO20083207L (no) Inhibitorer av IAP
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20063028L (no) 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2009016462A3 (fr) Bicyclolactames substitués
NO20090628L (no) Pyridizinon derivativater
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20070323L (no) Organiske forbindelser
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20081217L (no) Nye benzotiazolonderivater
NO20081844L (no) Terapeutiske forbindelser
NO20082496L (no) Pyrazinderivater
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application